Breast Cancer: Pathology, Biomarkers and Treatment
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Physiology and Pathology".
Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 4014
Special Issue Editors
Interests: breast cancer; nutrition
Interests: breast cancer; biomarker; luminal; HER2; triple-negative
Special Issue Information
Dear Colleagues,
It is well known that breast cancer is a heterogeneous disease with multiple intrinsic tumors, which are most commonly grouped into four major subtypes: luminal A, luminal B, HER2-overexpressing, and triple-negative (or basal-like).
Over the past few years, various therapies have emerged in the area of breast cancer. These include the most recently approved drugs, such as CDK 4/6 inhibitors in luminal subtypes, and antibody–drug conjugates, such as sacituzumab govitecan in triple-negative breast cancer or trastuzumab deruxtecan in HER2-overexpressing breast cancer. However, despite the use of the abovementioned subtype classifications to guide treatment regimes, many patients develop drug resistance and experience relapses or complete treatment failure.
We are looking for reviews or articles written by leading experts in their fields on the subjects of breast cancer subtypes and the different combinations of morphologic, clinical, immunohistochemical, and genomic characteristics. These should help provide a molecular spectrum of tumors with a better granular characterization to aid diagnoses, prognoses, and treatment regimes.
Dr. Elena Fiorio
Dr. Elena Giontella
Dr. Francesca Zacchi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- breast cancer
- subtypes
- biomarkers
- genomic alterations
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
